Market LIVE
Published markets; coverage varies by country
Product profile · United States

GIVLAARI

 ·  Patent Litigation & Settlement History ↓

IngredientGIVOSIRAN SODIUM
Application typeNDA
Application212194
Product001
Dosage formSOLUTION
RouteSUBCUTANEOUS
StrengthEQ 189MG BASE/ML (EQ 189MG BASE/ML)
Approval date2019-11-20
Marketing statusPrescription
Status event—
ApplicantALNYLAM PHARMS INC
Product source

Current GenericRadar decision

Year2034
SelectionCANDIDATE
ReviewFINAL
Anchor typeTRUE_DS_PATENT
Anchor date2034-10-03
Patent anchor2034-10-03
Exclusivity anchor2026-11-20
Protection date2034-10-03
First Final ANDA—
Status event—

US10119143 c20; givosiran strands/modifications/L96 compared. US11028392 same date.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
101319072028-08-24DS/DP/U U-2672YNTRUE_DS
| B1C03P8 issued-claim review2026-10-15: TRUE_DS
———
101319072028-08-24ORANGE_BOOK U-2672YNTRUE_DS
English description not available.
———
88289562028-12-04DS/DP/U U-2672YNTRUE_DS
| B1C03P8 issued-claim review2026-10-15: TRUE_DS
———
88289562028-12-04ORANGE_BOOK U-2672YNTRUE_DS
English description not available.
———
81060222029-12-12DS/DP/U U-2672YNTRUE_DS
| B1C03P8 issued-claim review2026-10-15: TRUE_DS
———
81060222029-12-12ORANGE_BOOK U-2672YNTRUE_DS
English description not available.
———
101253642033-03-15DS/DP/U U-2672YNTRUE_DS
| B1C03P8 issued-claim review2026-10-15: TRUE_DS
———
101253642033-03-15ORANGE_BOOK U-2672YNTRUE_DS
English description not available.
———
96311932033-03-15U U-2672NYU
| B1C03P8 issued-claim review2026-10-15: U
———
96311932033-03-15ORANGE_BOOK U-2672NYU
English description not available.
———
91334612033-11-20DS/DP/U U-2672YNTRUE_DS
| B1C03P8 issued-claim review2026-10-15: TRUE_DS
———
91334612033-11-20ORANGE_BOOK U-2672YNTRUE_DS
English description not available.
———
101191432034-10-03DS/DP/U U-2672YNTRUE_DS
| B1C03P8 issued-claim review2026-10-15: TRUE_DS
———
101191432034-10-03ORANGE_BOOK U-2672YNTRUE_DS
English description not available.
———
110283922034-10-03DS/DP/U U-2672YNTRUE_DS
| B1C03P8 issued-claim review2026-10-15: TRUE_DS
———
110283922034-10-03ORANGE_BOOK U-2672YNTRUE_DS
English description not available.
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
NCE2019-11-202024-11-20English description not available.YY2024-11-20
ODE-273
Full coverage date: 2024-11-20
Source
ODE-2732019-11-202026-11-20English description not available.YY2026-11-20—Source
ODE-2732019-11-202026-11-20English description not available.YY2026-11-20
ODE-273
Full coverage date: 2026-11-20
Source

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (1)
TypeDateRoleBasisSource
ANNUAL_DECISION_RECHECK—ANCHOR_AND_TAILUS10119143 c20; givosiran strands/modifications/L96 compared. US11028392 same date.Source
Decision history
CurrentYearStatusReviewAnchorJudged
Y2034CANDIDATEFINAL2034-10-032026-10-17 20:32:21
N2034CANDIDATEFINAL2034-10-032026-10-15 03:06:32
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.